Skip to main content
TipRanks
Go Ultimate75% OFF

Organigram Global (0OG) AI Stock Analysis

2 Followers
DE:0OG

Organigram Global

(Frankfurt:0OG)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and Margin GrowthStrong quarterly growth combined with substantial adjusted margin expansion indicates improving scale and operating execution. If sustained, higher revenue and gross profit can strengthen reinvestment capacity, support brand development, and move the business toward more durable operating profitability.
Negative Factors
Weak Core ProfitabilityNegative gross and operating margins show that the core business has not yet converted higher revenue into dependable operating earnings. This limits the company’s ability to self-fund growth and makes future profitability dependent on sustained pricing, mix, and efficiency improvements.

Organigram Global (0OG) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:0OG-40.00%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 116.84M
Dividend Yield
―
Average Volume (3M)
1,382
Price to Earnings (P/E)
1.8
Beta (1Y)
0.80
Revenue Growth
30.51%
EPS Growth
1974.35%
Country
Germany
Employees
1,139
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Organigram Global Business Overview & Revenue Model

Company Description

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and co...

Organigram Global Earnings Call Summary

Earnings Call Date:Aug 11, 2026(Q3-2026)|% Change Since:-9.64%|Next Earnings Date:Jan 12, 2021
Earnings Call SentimentPositive

The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.

Positive Updates

Record Quarterly Revenue and Accretive Acquisition
Net revenue of $105.8M, up 49% YoY from $70.8M. Contribution from Sanity Group: ~EUR 24.5M since acquisition (≈CAD $40M) and EUR 25.5M for the full quarter, in line with acquisition expectations.

Negative Updates

Negative Free Cash Flow and Working Capital Build
Free cash flow outflow of $3.9M for the quarter vs inflow of $5.0M prior year. Cash used in operating activities was $4.3M vs cash provided of $14.6M prior year, largely due to working capital investments (inventory build to address German demand and timing of sales). Company expects negative free cash flow for the full fiscal year.

Company Guidance

Management guided full‑year fiscal 2026 revenue to exceed $350 million, with adjusted gross margin and adjusted EBITDA expected to meaningfully exceed fiscal 2025 levels; they reiterated Sanity is expected to average ~EUR 25 million of quarterly revenue (Sanity delivered EUR 24.5M since April 15 and EUR 25.5M for the full quarter), international sales now constitute ~35% of consolidated revenue (vs ~10% pre‑acquisition), and they expect Q4 to outperform Q3. They cautioned that working‑capital investments tied to the Sanity integration will result in negative free cash flow for the full year (Q3 free cash flow was an outflow of $3.9M) but forecast positive free cash flow in Q4; Q3 results underpinning the outlook included record net revenue of $105.8M, adjusted gross margin of 37% (+300 bps YoY, +600 bps QoQ), record adjusted EBITDA of $13.4M, cash & equivalents of $11.7M and total liquidity of $49.2M. Management also noted Sanity margins are in line with expectations, Germany demand remains strong with minimal price compression, and that achieving EU‑GMP would meaningfully improve margins going forward.

Organigram Global Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0OG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:CRONTSE:CRON83OutperformCAD 1.77B21.005.35%―54.74%60.60%
TSE:GTIITSE:GTII69NeutralCAD 1.92B14.385.30%―6.44%127.50%
TSE:CURATSE:CURA60NeutralCAD 2.97B-217.45-1.47%―5.01%92.12%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:ACBTSE:ACB51NeutralCAD 463.50M-5.25-15.33%―-22.16%-30.78%
TSE:WEEDTSE:WEED48NeutralCAD 364.19M-1.06-39.36%―10.67%74.14%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:0OGTSE:WEEDTSE:ACBTSE:CRONTSE:CURATSE:GTIIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:0OG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0OGOrganigram Global Inc.0.75-0.52-40.94%
TSE:WEEDCanopy Growth0.81-0.66-44.90%
TSE:ACBAurora Cannabis (US)7.051.0016.53%
TSE:CRONCronos Group (US)4.821.4241.76%
TSE:CURACuraleaf Holdings (Otc)11.212.7232.04%
TSE:GTIIGreen Thumb Industries (OTC)8.740.799.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.